Agios Pharmaceuticals Seeks Accelerated Approval for Mitapivat
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Should l Buy AGIO?
Source: Newsfilter
Agios Pharmaceuticals Inc. shares surged by 14.83% as the stock crossed above the 5-day SMA, reflecting strong investor interest.
The company has submitted a proposal for a confirmatory clinical trial to the FDA for Mitapivat, aimed at supporting its accelerated approval in sickle cell disease. This proactive step follows promising results from the RISE UP Phase 3 trial, which showed significant improvements in hemoglobin levels, although pain crisis rates did not reach statistical significance. The upcoming submission of a supplemental New Drug Application (sNDA) highlights Agios's commitment to expedite market entry for this critical treatment.
The potential approval of Mitapivat could significantly enhance treatment options for patients with sickle cell disease, a market projected to grow substantially, thereby improving Agios's market position and investor confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGIO
Wall Street analysts forecast AGIO stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 27.070
Low
25.00
Averages
36.14
High
62.00
Current: 27.070
Low
25.00
Averages
36.14
High
62.00
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AGIOS PHARMACEUTICALS INC: H.C. Wainwright Lowers Price Target from $65 to $50
- Price Adjustment: The price of H.C. Wainwright's target for A.G.I.O. Pharmaceuticals has been reduced from $65 to $50.
- Market Impact: This price cut may reflect changes in market conditions or company performance expectations.
See More
Novo's Successful Trial Impacts Agios Stock Performance
- Novo Trial Success: Novo's Phase 3 trial of Etavopivat for sickle cell disease met both primary endpoints, significantly reducing painful vaso-occlusive crises and delaying the median time to first crisis by nearly four months, showcasing its competitive edge in the treatment landscape.
- Agios Stock Decline: Following Novo's positive trial results, Agios Pharmaceuticals (AGIO) shares plummeted over 25% on Monday, snapping a five-day winning streak, raising concerns about its future competitiveness with AGIO trading around $27.
- Competitive Pressure: Truist analyst noted that Novo's favorable data could exert pressure on Agios' stock, limiting its ability to rebound towards $40, although he remains optimistic about Mitapivat's potential in treating sickle cell disease.
- Investor Sentiment Shift: Despite the sharp decline in AGIO shares, retail investor sentiment shifted to 'bullish', indicating confidence in AGIO as a long-term investment, reflecting the market's complex view on its future performance.
See More
Agios Pharmaceuticals Shares Plunge 23% Amid Competitive Drug News
- Significant Stock Drop: Agios Pharmaceuticals' shares plummeted by 23% today, falling from $26.99 to $20.84, reflecting market concerns over its earnings potential amid competitive pressures from rival drugs.
- Competitive Drug Success: Novo Nordisk's etavopivat successfully met both co-primary endpoints in the HIBISCUS phase 3 trial, demonstrating significant efficacy, which poses a direct threat to Agios' mitapavit and its market position.
- Trial Results Comparison: While Agios' mitapavit showed improvements in hemoglobin levels for sickle cell disease patients, it failed to achieve statistically significant results in reducing pain crisis rates, further complicating its market outlook.
- Extended FDA Approval Path: Agios is working with the FDA to align on the confirmatory clinical trial required for submission, but compared to Novo's advancements, its path to approval appears longer and more uncertain, potentially undermining investor confidence.
See More
Agios Pharmaceuticals Under Investigation Following Phase 3 Trial Results, Stock Plummets
- Investigation Launched: Levi & Korsinsky has initiated an investigation into Agios Pharmaceuticals, Inc. regarding potential violations of federal securities laws, indicating serious concerns about the company's compliance practices.
- Clinical Trial Results: On November 19, 2025, Agios reported that its RISE UP Phase 3 trial met one primary endpoint but failed to show statistically significant improvement in annualized pain crises, highlighting limitations in treatment efficacy.
- Stock Price Reaction: Following the trial results, Agios' stock plummeted by $22.33 to open at $23.16, reflecting a significant decline in market confidence regarding the company's future prospects, which may impact its ability to raise capital.
- Investor Impact: The investigation and stock drop could erode investor trust in Agios, further affecting its market performance and shareholder value, underscoring the company's inadequate risk management in clinical development.
See More
Health Care Stocks Rise 2% Boosting Market
- Strong Performance in Health Care: Late Tuesday afternoon, the NYSE Health Care Index rose by 2%, indicating a rebound in investor confidence towards the health sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in health care stocks reflects optimistic expectations for economic recovery, particularly post-pandemic, as demand for health services continues to grow, potentially boosting the performance of related companies.
- Increased Investor Attention: With the improved performance of the health care sector, investors may reassess their portfolios and increase allocations to health stocks, thereby driving further growth and stability in the industry.
- Optimistic Industry Outlook: The strong performance in the health sector could attract more capital inflows, especially in the fields of innovative drugs and medical technologies, which are expected to provide momentum for future growth.
See More
Agios Pharmaceuticals Accelerates FDA Approval for Mitapivat
- Accelerated FDA Approval: Agios Pharmaceuticals' recent meeting with the FDA has laid the groundwork for a proposal for a confirmatory clinical trial for mitapivat, with expectations to submit a request for accelerated full approval within the next few months, potentially expediting the drug's market entry for sickle cell disease treatment.
- Significant Market Potential: The sickle cell disease therapy market, currently valued at approximately $4 billion, is projected to grow to over $14 billion by 2034, with mitapivat poised to expand market size by providing a much-needed effective treatment option.
- Strong Clinical Trial Performance: Mitapivat has shown promising results in the RISE UP trials and is already approved for various forms of anemia, with the FDA's special regulatory consideration highlighting the urgent need for new therapies in the sickle cell disease space.
- Positive Investor Reaction: Following the FDA's recommendation for a simplified confirmatory trial, Agios shares surged by 21.7%, indicating strong market optimism regarding the drug's prospects, despite the company's ongoing losses, suggesting potential for further stock price appreciation for risk-tolerant investors.
See More
AGIOS PHARMACEUTICALS INC: H.C. Wainwright Lowers Price Target from $65 to $50
- Price Adjustment: The price of H.C. Wainwright's target for A.G.I.O. Pharmaceuticals has been reduced from $65 to $50.
- Market Impact: This price cut may reflect changes in market conditions or company performance expectations.
See More
Novo's Successful Trial Impacts Agios Stock Performance
- Novo Trial Success: Novo's Phase 3 trial of Etavopivat for sickle cell disease met both primary endpoints, significantly reducing painful vaso-occlusive crises and delaying the median time to first crisis by nearly four months, showcasing its competitive edge in the treatment landscape.
- Agios Stock Decline: Following Novo's positive trial results, Agios Pharmaceuticals (AGIO) shares plummeted over 25% on Monday, snapping a five-day winning streak, raising concerns about its future competitiveness with AGIO trading around $27.
- Competitive Pressure: Truist analyst noted that Novo's favorable data could exert pressure on Agios' stock, limiting its ability to rebound towards $40, although he remains optimistic about Mitapivat's potential in treating sickle cell disease.
- Investor Sentiment Shift: Despite the sharp decline in AGIO shares, retail investor sentiment shifted to 'bullish', indicating confidence in AGIO as a long-term investment, reflecting the market's complex view on its future performance.
See More
Agios Pharmaceuticals Shares Plunge 23% Amid Competitive Drug News
- Significant Stock Drop: Agios Pharmaceuticals' shares plummeted by 23% today, falling from $26.99 to $20.84, reflecting market concerns over its earnings potential amid competitive pressures from rival drugs.
- Competitive Drug Success: Novo Nordisk's etavopivat successfully met both co-primary endpoints in the HIBISCUS phase 3 trial, demonstrating significant efficacy, which poses a direct threat to Agios' mitapavit and its market position.
- Trial Results Comparison: While Agios' mitapavit showed improvements in hemoglobin levels for sickle cell disease patients, it failed to achieve statistically significant results in reducing pain crisis rates, further complicating its market outlook.
- Extended FDA Approval Path: Agios is working with the FDA to align on the confirmatory clinical trial required for submission, but compared to Novo's advancements, its path to approval appears longer and more uncertain, potentially undermining investor confidence.
See More
Agios Pharmaceuticals Under Investigation Following Phase 3 Trial Results, Stock Plummets
- Investigation Launched: Levi & Korsinsky has initiated an investigation into Agios Pharmaceuticals, Inc. regarding potential violations of federal securities laws, indicating serious concerns about the company's compliance practices.
- Clinical Trial Results: On November 19, 2025, Agios reported that its RISE UP Phase 3 trial met one primary endpoint but failed to show statistically significant improvement in annualized pain crises, highlighting limitations in treatment efficacy.
- Stock Price Reaction: Following the trial results, Agios' stock plummeted by $22.33 to open at $23.16, reflecting a significant decline in market confidence regarding the company's future prospects, which may impact its ability to raise capital.
- Investor Impact: The investigation and stock drop could erode investor trust in Agios, further affecting its market performance and shareholder value, underscoring the company's inadequate risk management in clinical development.
See More
Health Care Stocks Rise 2% Boosting Market
- Strong Performance in Health Care: Late Tuesday afternoon, the NYSE Health Care Index rose by 2%, indicating a rebound in investor confidence towards the health sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in health care stocks reflects optimistic expectations for economic recovery, particularly post-pandemic, as demand for health services continues to grow, potentially boosting the performance of related companies.
- Increased Investor Attention: With the improved performance of the health care sector, investors may reassess their portfolios and increase allocations to health stocks, thereby driving further growth and stability in the industry.
- Optimistic Industry Outlook: The strong performance in the health sector could attract more capital inflows, especially in the fields of innovative drugs and medical technologies, which are expected to provide momentum for future growth.
See More
Agios Pharmaceuticals Accelerates FDA Approval for Mitapivat
- Accelerated FDA Approval: Agios Pharmaceuticals' recent meeting with the FDA has laid the groundwork for a proposal for a confirmatory clinical trial for mitapivat, with expectations to submit a request for accelerated full approval within the next few months, potentially expediting the drug's market entry for sickle cell disease treatment.
- Significant Market Potential: The sickle cell disease therapy market, currently valued at approximately $4 billion, is projected to grow to over $14 billion by 2034, with mitapivat poised to expand market size by providing a much-needed effective treatment option.
- Strong Clinical Trial Performance: Mitapivat has shown promising results in the RISE UP trials and is already approved for various forms of anemia, with the FDA's special regulatory consideration highlighting the urgent need for new therapies in the sickle cell disease space.
- Positive Investor Reaction: Following the FDA's recommendation for a simplified confirmatory trial, Agios shares surged by 21.7%, indicating strong market optimism regarding the drug's prospects, despite the company's ongoing losses, suggesting potential for further stock price appreciation for risk-tolerant investors.
See More
